Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 

    Article Cited by others

ORIGINAL ARTICLE

Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer

Li Wenhong, Wei Zhigang, Yang Xia, Huang Guanghui, Han Xiaoying, Ni Yang, Wang Jiao, Meng Min, Zou Zhigeng, Wen Qiang, Ye Xin

Year : 2019| Volume: 15| Issue : 7 | Page no: 1624-1628

   This article has been cited by
 
1 TACE plus PD-1 inhibitor (Camrelizumab) treatment for bridging to tumor resection in HCC: Case reports
Haibei Xin, Cunzhen Zhang, Zhiwen Ding, Minfeng Zhang, Guanghui Ding, Nan Li
Clinics and Research in Hepatology and Gastroenterology. 2022; 46(1): 101777
[Pubmed]  [Google Scholar] [DOI]
2 Case Report: Addition of PD-1 Antibody Camrelizumab Overcame Resistance to Trastuzumab Plus Chemotherapy in a HER2-Positive, Metastatic Gallbladder Cancer Patient
Li Wang, Xiaomo Li, Yurong Cheng, Jing Yang, Si Liu, Tonghui Ma, Li Luo, Yanping Hu, Yi Cai, Dong Yan
Frontiers in Immunology. 2022; 12
[Pubmed]  [Google Scholar] [DOI]
3 Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
Fei Yang, Jun Yang, Wei Xiang, Bin-Yan Zhong, Wan-Ci Li, Jian Shen, Shuai Zhang, Yu Yin, Hong-Peng Sun, Wan-Sheng Wang, Xiao-Li Zhu
Frontiers in Oncology. 2022; 11
[Pubmed]  [Google Scholar] [DOI]
4 Anlotinib combined with anti-PD-1 antibody, camrelizumab for advanced NSCLCs after multiple lines treatment: An open-label, dose escalation and expansion study
Na Zhou, Man Jiang, Tianjun Li, Jingjuan Zhu, Kewei Liu, Helei Hou, Xiaochun Zhang
Lung Cancer. 2021; 160(1): 111
[Pubmed]  [Google Scholar] [DOI]
5 Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns
Orla Cunningham, Martin Scott, Zhaohui Sunny Zhou, William J.J. Finlay
mAbs. 2021; 13(1)
[Pubmed]  [Google Scholar] [DOI]
6 The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
Jingjing Qu, Quanhui Mei, Li Liu, Tianli Cheng, Peng Wang, Lijun Chen, Jianying Zhou
Therapeutic Advances in Medical Oncology. 2021; 13: 1758835921
[Pubmed]  [Google Scholar] [DOI]
7

Emerging Targets of Immunotherapy in Gynecologic Cancer

Hongyan Cheng, Liju Zong, Yujia Kong, Yu Gu, Junjun Yang, Yang Xiang
OncoTargets and Therapy. 2020; Volume 13: 11869
[Pubmed]  [Google Scholar] [DOI]
8 The clinical application of camrelizumab on advanced hepatocellular carcinoma
Zhongguang Chen, Xiuhua Lu, Kelly Koral
Expert Review of Gastroenterology & Hepatology. 2020; 14(11): 1017
[Pubmed]  [Google Scholar] [DOI]

 

Read this article